Xortx Therapeutics Inc (XRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,656 | -2,066 | -1,416 | -699 | -3,313 |
| Depreciation Amortization | 112 | 83 | 54 | 26 | 117 |
| Accounts receivable | -63 | -5 | 7 | 0 | 43 |
| Other Working Capital | 336 | 389 | 333 | 267 | 117 |
| Other Operating Activity | -498 | -468 | -414 | -238 | -643 |
| Operating Cash Flow | $-2,769 | $-2,067 | $-1,437 | $-644 | $-3,679 |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | -55 | -31 | -25 | -3 | -39 |
| Other Investing Activity | -295 | -31 | -25 | -3 | -39 |
| Investing Cash Flow | $-295 | $-31 | $-25 | $-3 | $-39 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,256 | 1,153 | 114 | 114 | 3,517 |
| Other Financing Activity | -828 | -358 | -89 | -46 | -738 |
| Financing Cash Flow | $1,428 | $795 | $24 | $68 | $2,780 |
| Exchange Rate Effect | 27 | 23 | 28 | 1 | -36 |
| Beginning Cash Position | 2,474 | 2,474 | 2,474 | 2,474 | 3,448 |
| End Cash Position | 865 | 1,194 | 1,064 | 1,895 | 2,474 |
| Net Cash Flow | $-1,609 | $-1,280 | $-1,410 | $-578 | $-974 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,769 | -2,067 | -1,437 | -644 | -3,679 |
| Free Cash Flow | -2,769 | -2,067 | -1,437 | -644 | -3,679 |